Literature DB >> 17459268

Management of the complications of radical prostatectomy.

Penner Schraudenbach1, Carlos E Bermejo.   

Abstract

Over the past several years, the morbidity associated with radical prostatectomy has improved due to advances in surgical technique, better understanding of male pelvic anatomy, and improved perioperative care. Despite these advances, patients are still at risk for several complications both intraoperatively and in the postoperative course. These risks include significant blood loss, rectal injury, ureteral injury, thromboembolic events, urinary incontinence, impotence, and a perioperative death rate of less than 1%. These risks should be reviewed and discussed before treating the patient with prostate cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17459268     DOI: 10.1007/s11934-007-0006-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  42 in total

1.  Postoperative radiation therapy after radical prostatectomy for prostate carcinoma.

Authors:  R Meier; R Mark; L St Royal; L Tran; G Colburn; R Parker
Journal:  Cancer       Date:  1992-10-01       Impact factor: 6.860

2.  Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial.

Authors:  S W Bigg; W J Catalona
Journal:  Urology       Date:  1992-04       Impact factor: 2.649

3.  Perioperative and postoperative complications from bilateral pelvic lymphadenectomy and radical retropubic prostatectomy.

Authors:  T C Igel; D M Barrett; J W Segura; R C Benson; C C Rife
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

4.  Endoscopic extraperitoneal radical prostatectomy: oncological and functional results after 700 procedures.

Authors:  Jens-Uwe Stolzenburg; Robert Rabenalt; Minh DO; Kossen Ho; Wolfgang Dorschner; Eginhard Waldkirch; Udo Jonas; Alexander Schütz; Lars Horn; Michael C Truss
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

5.  Impotence following radical prostatectomy: insight into etiology and prevention.

Authors:  P C Walsh; P J Donker
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

6.  Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles.

Authors:  D M Quinlan; J I Epstein; B S Carter; P C Walsh
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

7.  Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy.

Authors:  J Kellogg Parsons; Penny Marschke; Patricia Maples; Patrick C Walsh
Journal:  Urology       Date:  2004-11       Impact factor: 2.649

8.  Postoperative bleeding following radical retropubic prostatectomy.

Authors:  S P Hedican; P C Walsh
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

Review 9.  Incontinence and vesical neck strictures following radical retropubic prostatectomy.

Authors:  E S Geary; T E Dendinger; F S Freiha; T A Stamey
Journal:  Urology       Date:  1995-06       Impact factor: 2.649

10.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

Authors:  H Zincke; J E Oesterling; M L Blute; E J Bergstralh; R P Myers; D M Barrett
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  3 in total

1.  Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.

Authors:  David A Brown; Fredrik Lindmark; Pär Stattin; Katarina Bälter; Hans-Olov Adami; Sigun L Zheng; Jianfeng Xu; William B Isaacs; Henrik Grönberg; Samuel N Breit; Fredrik E Wiklund
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

2.  Established prostate cancer susceptibility variants are not associated with disease outcome.

Authors:  Fredrik E Wiklund; Hans-Olov Adami; Sigun L Zheng; Pär Stattin; William B Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

Review 3.  Management of complications of prostate cancer treatment.

Authors:  M Dror Michaelson; Shane E Cotter; Patricio C Gargollo; Anthony L Zietman; Douglas M Dahl; Matthew R Smith
Journal:  CA Cancer J Clin       Date:  2008-05-23       Impact factor: 508.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.